Literature DB >> 32271897

Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Romain Lévy1,2, Mathieu Fusaro1,3, Frédéric Guerin1, Ahmed Chetouani4, Despina Moshous1,2, Alain Fischer1,2,5, Geneviève de Saint Basile1,3, Fernando E Sepulveda1,6, Bénédicte Neven1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32271897      PMCID： PMC7160282          DOI： 10.1182/bloodadvances.2020001497

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  21 in total

1.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.

Authors:  Jessica Slostad; Patrick Hoversten; Candace L Haddox; Kamila Cisak; Jonas Paludo; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

4.  Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy.

Authors:  David Michonneau; Tony Petrella; Nicolas Ortonne; Saskia Ingen-Housz-Oro; Nathalie Franck; Stéphane Barete; Maxime Battistella; Marie Beylot-Barry; Béatrice Vergier; Marc Maynadié; Christine Bodemer; Olivier Hermine; Martine Bagot; Nicole Brousse; Sylvie Fraitag
Journal:  Acta Derm Venereol       Date:  2017-03-10       Impact factor: 4.437

5.  Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential.

Authors:  Alison R Huppmann; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

Review 6.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis.

Authors:  H Takada; Y Takahata; A Nomura; S Ohga; Y Mizuno; T Hara
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.

Authors:  Sophia Maschalidi; Fernando E Sepulveda; Alexandrine Garrigue; Alain Fischer; Geneviève de Saint Basile
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

9.  Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Rupali Das; Peng Guan; Leslee Sprague; Katherine Verbist; Paige Tedrick; Qi Angel An; Cheng Cheng; Makoto Kurachi; Ross Levine; E John Wherry; Scott W Canna; Edward M Behrens; Kim E Nichols
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

10.  [Refractory/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib: three cases report and literatures review].

Authors:  J S Wang; Y N Wang; L Wu; W Y Lai; Z Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14
View more
  6 in total

Review 1.  Maximizing insights from monogenic immune disorders.

Authors:  Anis Barmada; Anjali Ramaswamy; Carrie L Lucas
Journal:  Curr Opin Immunol       Date:  2021-10-22       Impact factor: 7.486

2.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 3.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

Authors:  Camille Keenan; Kim E Nichols; Sabrin Albeituni
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

4.  Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

Authors:  Xiang Liu; Xueling Zhu; Xiaotang Zhou; Yirui Xie; Dairong Xiang; Zhikai Wan; Ying Huang; Biao Zhu
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 5.  [PD-1 monoclonal antibody combined with chemotherapy in the treatment of subcutaneous panniculitis-like T-cell lymphoma: a case report and literature review].

Authors:  S Qu; L S Liao; Y Xie; Z H Zheng; B Y Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-11-14

Review 6.  Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.

Authors:  Karol Kołkowski; Magdalena Trzeciak; Małgorzata Sokołowska-Wojdyło
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.